Stay updated on Entinostat Plus Pembrolizumab in Advanced Cancers Clinical Trial
Sign up to get notified when there's something new on the Entinostat Plus Pembrolizumab in Advanced Cancers Clinical Trial page.

Latest updates to the Entinostat Plus Pembrolizumab in Advanced Cancers Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has removed extensive details about a clinical study involving entinostat and pembrolizumab for various cancers, while adding new identifiers and collaborators related to the study.SummaryDifference30%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 20, 2025.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has updated its posting dates and revision number, indicating a more recent version of the content. The estimated dates have been replaced with specific dates, which may reflect more accurate information.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to include detailed information about a Phase 1b/2 study of entinostat combined with pembrolizumab for treating non-small cell lung cancer (NSCLC), melanoma, and colorectal cancer, including specific eligibility criteria and treatment protocols. Additionally, new results reporting dates and study documentation have been added.SummaryDifference90%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
Stay in the know with updates to Entinostat Plus Pembrolizumab in Advanced Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Entinostat Plus Pembrolizumab in Advanced Cancers Clinical Trial page.